EGFR-targeting drugs could be considered as NPC anti-tumor drugs, and recently, therapies targeting the EGFR in NPC have included monoclonal humanized antibodies (CTX, NTZ and Panitumumab), selective small molecule inhibitors (Gefitinib, Erlotinib, and Afatinib), PI3K inhibitors, and antisense gene therapy [32,91]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.